共 84 条
[1]
Achenbach S(2012)Kommentar zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie des akuten Koronarsyndroms ohne persistierende ST-Streckenhebung Kardiologe 6 283-301
[2]
Szardien S(2017)Management of patients on non–vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association Circulation 33 1595-1604
[3]
Zeymer U(2017)Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States medicare population Curr Med Res Opin 110 588-636
[4]
Amin A(2014)2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: a report of the American college of cardiology/American heart association task force on practice guidelines J Am Coll Cardiol 9 1322-1524
[5]
Keshishian A(2004)ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary Circulation 377 1513-194
[6]
Trocio J(2018)Antithrombotic regimens in patients with percutaneous coronary intervention whom an anticoagulant is indicated: a systematic review and network meta-analysis Front Pharmacol 179 186-390
[7]
Amsterdam EA(2017)Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation N Engl J Med 11 381-2434
[8]
Wenger NK(2019)Association of parenteral anticoagulation therapy with outcomes in Chinese patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome JAMA Intern Med 375 2423-78
[9]
Brindis RG(2015)Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial EuroIntervention 114 70-177
[10]
Antman EM(2016)Prevention of bleeding in patients with atrial fibrillation undergoing PCI N Engl J Med 19 142-885